Our results show that co-treatment with quercetin and ZD55-TRAIL can cumulatively lower HCC cell survival both in vitro and in vivo and markedly increase apoptosis by activating caspase-9, caspase-3 and PARP. Here, CASP9 is linked to hepatocellular carcinoma.